Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology-Reference-Cited by-同舟云学术

Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology

Published:2021-03-26 Issue:10 Volume:32 Page:2603-2618
ISSN:0937-3462
Container-title:International Urogynecology Journal
language:en
Short-container-title:Int Urogynecol J

Author:

Dequirez Pierre-Luc^ORCID,Biardeau Xavier

Funder

Medtronic

Publisher

Springer Science and Business Media LLC

Subject

Urology,Obstetrics and Gynaecology

Link

https://link.springer.com/content/pdf/10.1007/s00192-021-04688-z.pdf

Reference42 articles.

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/s0090-4295(02)02243-4.

2. Overactive Bladder (OAB) Guideline - American Urological Association. Accessed August 1, 2020. https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline#x2907.

3. Marcelissen T, Cornu J-N, Antunes-Lopes T, et al. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? Eur Urol Focus. 2018;4(5):760–7. https://doi.org/10.1016/j.euf.2018.05.004.

4. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1.

5. Yokoyama O, Honda M, Yamanishi T, et al. OnabotulinumtoxinA (botulinum toxin type a) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol. 2020;27(3):227–34. https://doi.org/10.1111/iju.14176.